Abstract
The role of nonprofit organizations in drug development has evolved from a primary emphasis on grant funding to a driving force that is advancing scientific development and leading cutting edge research. The Multiple Myeloma Research Foundation (MMRF) is a leader in this field, and has recognized that despite recent advances, multiple myeloma patients’ responses to today’s treatments are variable and unpredictable, often based on the patient’s molecular profile. The MMRF believes all patients would benefit from the creation of new, personalized treatment approaches and is working to make this vision a reality with its ambitious Personalized Medicine Initiative. Most recently, MMRF launched the CoMMpassSM (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile) study to collect and analyze tissue samples and genetic information from approximately 1000 multiple myeloma patients over the next 5 years. The study is designed to tailor next-generation personalized multiple myeloma treatments.
Reference
- 1 Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature471,467–472 (2011).